Profile data is unavailable for this security.
About the company
Appili Therapeutics Inc. is a Canada-based biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures. The Company is advancing a diverse range of anti-infectives, including ready-made suspension of metronidazole for the treatment of antimicrobial infections, a vaccine candidate to eliminate a serious biological weapon threat, and a topical antiparasitic for the treatment of a disfiguring disease. Its anti-infective product development portfolio includes three programs: LIKMEZ (ATI-1501), ATI-1701 and ATI-1801. LIKMEZ (ATI-1501) is its advanced commercial stage asset, a liquid oral reformulation of the antibiotic metronidazole to treat serious anaerobic and protozoal infections. ATI-1701 is a live-attenuated vaccine for Francisella tularensis (F. tularensis), the bacterium which causes tularemia. ATI-1801 is a topical formulation of paromomycin (15% w/w) under advanced clinical development for the treatment of cutaneous leishmaniasis.
- Revenue in CAD (TTM)827.41k
- Net income in CAD-3.82m
- Incorporated2015
- Employees7.00
- LocationAppili Therapeutics Inc#21-1344 Summer StreetHALIFAX B3H 0A8CanadaCAN
- Phone+1 (902) 442-4655
- Fax+1 (902) 442-4655
- Websitehttps://appilitherapeutics.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CVR Medical Corp | 0.00 | -2.67m | 1.99m | -- | -- | -- | -- | -- | -0.0259 | -0.0259 | 0.00 | -0.0609 | 0.00 | -- | -- | -- | -322.06 | -341.11 | -- | -- | -- | -- | -- | -- | -- | -2.46 | -- | -- | -- | -- | -948.22 | -- | -- | -- |
| Appili Therapeutics Inc | 827.41k | -3.82m | 3.64m | 7.00 | -- | -- | -- | 4.40 | -0.0315 | -0.0315 | 0.0068 | -0.1021 | 0.3758 | -- | 0.6463 | 118,201.40 | -173.36 | -128.44 | -- | -251.87 | -- | -- | -461.35 | -2,103.81 | -- | -3.30 | -- | -- | 147.59 | -- | 59.09 | -- | 17.59 | -- |
| Marvel Biosciences Corp | 0.00 | -2.10m | 4.48m | -- | -- | -- | -- | -- | -0.0529 | -0.0529 | 0.00 | -0.0693 | 0.00 | -- | -- | -- | -268.48 | -- | -- | -- | -- | -- | -- | -- | -- | -14.33 | -- | -- | -- | -- | 10.29 | -- | -- | -- |
| StageZero Life Sciences Ltd | -100.00bn | -100.00bn | 4.90m | 40.00 | -- | -- | -- | -- | -- | -- | -- | -0.1119 | -- | -- | -- | -- | -- | -135.76 | -- | -- | -- | -2.74 | -- | -246.92 | 0.0176 | -- | -- | -- | -25.12 | 55.93 | -52.53 | -- | -- | -- |
| Innovotech Inc | 1.23m | -364.50k | 5.27m | 16.00 | -- | 7.22 | -- | 4.29 | -0.0094 | -0.0094 | 0.0315 | 0.0187 | 1.10 | 5.81 | 5.84 | -- | -32.59 | 2.90 | -37.99 | 3.56 | 68.63 | 71.56 | -29.67 | 2.19 | 2.17 | -- | 0.1115 | -- | 5.05 | 7.42 | -15.43 | -- | 35.69 | -- |
